Abstract
Heat shock proteins (HSPs) are ubiquitous and evolutionary conserved proteins induced by cell stress. HSP60, in particular, is a typical mitochondrial molecular chaperone that is known to assist nascent polypeptides to reach a native conformation. HSP60 is also known to interact with HSP10. In the last decade, HSP60 has been detected in the cytosol, the cell surface, the extracellular space, and biological fluids. HSP60 elicits potent proinflammatory response in cells of the innate immune system and serves as a danger signal of stressed or damaged cells. As cytosolic HSP60 levels gradually increase or decrease during carcinogenesis in various organs, HSP60 can be used as a biomarker for the diagnosis and prognosis of preneoplastic and neoplastic lesions. In this review, we summarize recent discoveries on the important roles of HSP60 in various diseases ranging from autoimmune diseases to tumors. Furthermore, small molecules targeting HSP60, which were the target of intensive investigations in the last few years, are also summarized. The possibility of utilizing HSP60 as a new drug target for the treatment of certain diseases is examined.
Keywords: HSP60, molecular chaperone, apoptosis, proinflammatory response, biomarker, carcinogenesis, inhibitor, cell stress, diagnosis, prognosis.
Current Pharmaceutical Design
Title:HSP60 as a Drug Target
Volume: 19 Issue: 3
Author(s): Hiroyuki Nakamura and Hidemitsu Minegishi
Affiliation:
Keywords: HSP60, molecular chaperone, apoptosis, proinflammatory response, biomarker, carcinogenesis, inhibitor, cell stress, diagnosis, prognosis.
Abstract: Heat shock proteins (HSPs) are ubiquitous and evolutionary conserved proteins induced by cell stress. HSP60, in particular, is a typical mitochondrial molecular chaperone that is known to assist nascent polypeptides to reach a native conformation. HSP60 is also known to interact with HSP10. In the last decade, HSP60 has been detected in the cytosol, the cell surface, the extracellular space, and biological fluids. HSP60 elicits potent proinflammatory response in cells of the innate immune system and serves as a danger signal of stressed or damaged cells. As cytosolic HSP60 levels gradually increase or decrease during carcinogenesis in various organs, HSP60 can be used as a biomarker for the diagnosis and prognosis of preneoplastic and neoplastic lesions. In this review, we summarize recent discoveries on the important roles of HSP60 in various diseases ranging from autoimmune diseases to tumors. Furthermore, small molecules targeting HSP60, which were the target of intensive investigations in the last few years, are also summarized. The possibility of utilizing HSP60 as a new drug target for the treatment of certain diseases is examined.
Export Options
About this article
Cite this article as:
Nakamura Hiroyuki and Minegishi Hidemitsu, HSP60 as a Drug Target, Current Pharmaceutical Design 2013; 19 (3) . https://dx.doi.org/10.2174/1381612811306030441
DOI https://dx.doi.org/10.2174/1381612811306030441 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Neutrophil: An Underappreciated But Key Player in SLE Pathogenesis
Current Immunology Reviews (Discontinued) Fc Receptors as Potential Targets for the Treatment of Allergy, Autoimmune Disease and Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Epigenetics in Ocular Diseases
Current Genomics miRNA Functions in Arthritis
Current Rheumatology Reviews Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets The Effects of Dehydroepiandrosterone (DHEA) in the Treatment of Depression and Depressive Symptoms in Other Psychiatric and Medical Illnesses: A Systematic Review
Current Drug Targets From Cannabis to Endocannabinoids in Multiple Sclerosis: A Paradigm of Central Nervous System Autoimmune Diseases
Current Drug Targets - CNS & Neurological Disorders Ulcerative Colitis: Pathogenesis
Current Drug Targets Biochemical Markers of Renal Function
Current Medicinal Chemistry Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod
Current Drug Targets The Expanding Role of APRIL in Cancer and Immunity
Current Molecular Medicine Interferon: Cellular Executioner or White Knight?
Current Medicinal Chemistry The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Pathophysiology of IgG4-Related Disease
Current Immunology Reviews (Discontinued) NF-κB Inhibitors for the Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Nucleic Acid Enzymes as a Novel Generation of Anti-gene Agents
Current Molecular Medicine Protein Engineering Studies for C-C Chemokine Receptor Type 2 (CCR2)
Current Enzyme Inhibition